Venecla, the world's first listed BCL-2 inhibitor, was approved in China

On January 13th Venetoclax, the selective inhibitor of AbbVie Bcl-2, the only apoptosis drug approved for sale in the world based on apoptosis mechanisms, was declared available in China.
is currently the only approved Bcl-2 selective inhibitor in the world, by inhibiting apoptosis Bcl-2 to promote CLL apoptosis.
Bcl-2 is a family of genes responsible for regulating apoptosis and plays an important role in maintaining cell survival and suppressing apoptosis.
Bcl-2 family can be divided into two categories, one is anti-apoptosis, mainly Bcl-2, Bcl-xL, Bcl-W, McL-1, CED9, the other is cell-promoting death, including Bax, Bak, Bcl-XS, Bad, Bik, Bid and so on.
, Bcl-2, Bcl-xL, and Mcl-1 are mainly located in the outer membrane of mitochondrials and are responsible for regulating the release of the important signaling molecule cytochrome C (Cytc) and SMAC in apoptosis cascading reactions.
cell pigment C can promote apoptosis, SMAC can promote apoptosis by inhibiting IAP.
Bcl-2 gene mutation is the main cause of many cancers, when the expression of anti-apoptosis gene in Bcl-2 blocks the release of cytochrome C and SMAC, thereby inhibiting apoptosis leading to cancer.
Venecla, developed by AbbVie, was awarded breakthrough treatment by the FDA in 2015 and approved by the FDA in 2016 for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
more than 80 clinical trials currently under way at Venetoclax, and based on the results of its first-line trials, Venecla may become a first-line drug for the treatment of CLL in the next few years.
2018 and 2019 H1, Venecla made $340 million and $320 million, respectively, and is expected to grow more than 100 percent for the full year of 2019, according to AbbVie.
AbbVie and Roche have jointly developed the BCL-2 inhibitor Venecla tablet, which has been approved for sale in China, according to the official website of the State Drug Administration.
their adaptive disorders are combined with other medications for patients aged 75 and older, or for adults with acute myeloid leukemia (AML) who are not suitable for a new diagnosis of strong-induced chemotherapy due to co-merger.
2016 in the U.S., the world's first BCL-2 inhibitor, according to new data.
sales of $972 million in the first three quarters of 2020 and annual sales of more than $1 billion are expected to be heavyweights for the companies.
related report: Venclyxto (venetoclax) treatment of chronic lymphocytic leukemia: NICE-supported NEJM: Venetoclax treatment of acute myeloid leukemia (AML), Phase III clinical positive results Blod: BTK inhibitor therapy cocoa Effective treatment of venetoclax drug-resistant CLLLancet Haematol: Venetoclax combined west tathamin 10-day therapy to treat a variety of AML subtype efficacy Blod: determine the molecular characteristics of AML elderly patients prognosticated by venetoclax combined chemotherapy! Network Source: Network Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here